A Phase 2 interventional study of LNP023 in Glomerulonephritis, sponsored by Novartis Pharmaceuticals. Completed at 9 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Glomerulonephritis with a site in France — 5 open to participants now, 8 under way, 5 of them phase 3. Glomerulonephritis · France.
Among the 13 studies in Glomerulonephritis with a site in France, this one is the 11th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 2, and was the 4th registered.
115 studies on the registry are indexed under Glomerulonephritis; 32 are open to participants now.
Browse Glomerulonephritis studies →5 of the 13 studies in Glomerulonephritis with a site in France are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in France, United States, China and 5 more countries
Ages 2–18
Swedish Orphan Biovitrum · Sites in France, Australia, Austria and 11 more countries
Alentis Therapeutics AG · Sites in France, Czechia, Denmark and 7 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Argentina and 33 more countries
Ages 18–100
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–84
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 26 Glomerulonephritis studies recruiting now, 15 (58%) set no upper age limit and 6 (23%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 50 across 87 interventional studies indexed under Glomerulonephritis.
Median enrollment 137 across the 12 interventional studies, 63 across the 1 observational. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Glomerulonephritis — fewer than ten, so there is no comparison to draw.
3 of the studies in Glomerulonephritis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06047171Alentis Therapeutics AGRescue of Nephrons With ALE.F02 (RENAL-F02) | 2027-06-30 |
| NCT07096986Centre Hospitalier Universitaire de NiceImpact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Glomerulonephritis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is an open-label, two cohort non-randomized study evaluating the efficacy, safety, and pharmacokinetics of LNP023 in patients with C3G (Cohort A) and patients who have undergone kidney transplant and have C3G recurrence (Cohort B).
Inclusion Criteria for Cohort A and B:
oral body temperature between 35.0-37.5 °C systolic blood pressure, 80-170 mm Hg diastolic blood pressure, 50-105 mm Hg pulse rate, 45 - 100 bpm
.
Inclusion Criteria for Cohort A:
Inclusion Criteria for Cohort B:
Exclusion Criteria for Cohort A and B:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
C3G patients who have not received a kidney transplant and have reduced C3 blood levels.
Drug: LNP023
C3G patients who have received a kidney transplant and have C3G recurrence.
Drug: LNP023
Increasing doses of LNP023 up to 200 mg.
Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR)
Change in proteinuria assessed by ratio to baseline of UPCR derived from 24h urine collection
Time frame: Week 12
Cohort B: Change From Baseline in C3 Deposit
Histopathological changes in kidney biopsies as assessed by change from baseline in C3 Deposit Score (based on immunofluorescence microscopy)
Time frame: Week 12
Change From Baseline in Urine Protein Creatinine Concentration Ratio (UPCR)
Ratio to baseline UPCR derived from 24 hour urine collection
Time frame: Week 12: Day 84
Change From Baseline in Urine Protein (UP) Excretion
Ratio to baseline UP excretion derived from 24 hour urine collection
Time frame: Week 12: Day 84
Change From Baseline in Urine Albumin Creatinine Concentration Ratio (UACR) Excretion
Ratio to baseline UACR excretion derived from 24 hour urine collection
Time frame: Week 12: Day 84
Change From Baseline Change in Urinary Albumin (UA) Excretion
Ratio to baseline UA excretion derived from 24 hour urine collection
Time frame: Week 12: Day 84
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
Effect of LNP023 on estimated glomerular filtration rate (eGFR)
Time frame: Day 84
Change From Baseline in Serum Creatinine
The effect of LNP023 on renal function - serum creatinine
Time frame: Week 12: Day 84
Change From Baseline in Creatinine Clearance
The effect of LNP023 on renal function - creatinine clearance
Time frame: Week 12: Day 84
Number of Patients With Hematuria
The effect of LNP023 on renal function - hematuria
Time frame: Week 12: Day 84
Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) First Morning Void
Ratio to baseline of UPCR reduction derived from total cumulative urinary excretion first morning void
Time frame: Week 9: Day 64
Change From Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR) First Morning Void
UACR reduction derived from total cumulative urinary excretion first morning void
Time frame: Week 9: Day 64
Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUClast (AUC)
The area under the plasma concentration-time curve calculated from time zero to the last quantifiable concentration point (hr\*ng/mL)
Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUCtau (AUC)
The area under the plasma concentration-time curve calculated to the end of the dosing interval (hr\*ng/mL)
Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Observed Maximum Concentration After Drug Administration (Cmax)
The observed maximum plasma concentration (ng/mL)
Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Observed Minimum Concentration After Drug Administration (Ctrough)
The concentration that is just prior to the beginning of, or at the end, of a dosing interval (ng/mL)
Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Time to Reach the Maximum Plasma Concentration (Tmax)
The time to reach peak or maximum concentration (hr)
Time frame: Day 7, Day 14, Day 21, Day 28 (pre-dose, 0.5h, 1h, 2h, 4h, 6h, 8h post dose) and Day 36, Day 64 and Day 84 (pre-dose)
Summary of Change From Baseline Complement C3 Biomarker in Serum
To assess the effect of LNP023 on alternative complement pathway hyperactivity.
Time frame: Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
Ratio to Baseline Summary of Plasma Bb
To assess the relationship between LNP023 dose and pharmacodynamic biomarker levels of blood Bb
Time frame: Baseline, Day 1, Day 7, Day 14, Day 21, Day 28, Day 36, Day 64, Day 84
A total of 27 patients (16 patients in Cohort A and 11 patients in Cohort B) were enrolled and treated in the treatment period 1. All 27 patients completed the study and there were no patients who discontinued the study.
| Milestone | Cohort A: Run-In Phase | Cohort B: Run-In Phase | Cohort A: Dose Escalation/LNP023 Treatment 200 mg b.i.d | Cohort B - Dose Escalation/LNP023 Treatment 200 mg b.i.d |
|---|---|---|---|---|
| Started | 16 | 11 | 0 | 0 |
| Completed | 16 | 11 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Cohort A: Run-In Phase | Cohort B: Run-In Phase | Cohort A: Dose Escalation/LNP023 Treatment 200 mg b.i.d | Cohort B - Dose Escalation/LNP023 Treatment 200 mg b.i.d |
|---|---|---|---|---|
| Started | 0 | 0 | 16 | 11 |
| Completed | 0 | 0 | 16 | 11 |
| Not completed | 0 | 0 | 0 | 0 |
Change in proteinuria assessed by ratio to baseline of UPCR derived from 24h urine collection
| ratio | Cohort A - no Kidney Transplant |
|---|---|
| Cohort A: Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) | 0.55 (0.46 to 0.65) |
Histopathological changes in kidney biopsies as assessed by change from baseline in C3 Deposit Score (based on immunofluorescence microscopy)
| Percentage change | Cohort B - Kidney Transplant |
|---|---|
| Cohort B: Change From Baseline in C3 Deposit | -2.50 (-3.75 to -0.75) |
Ratio to baseline UPCR derived from 24 hour urine collection
| ratio | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline in Urine Protein Creatinine Concentration Ratio (UPCR) | 0.55 (0.46 to 0.65) | 0.79 (0.49 to 1.28) |
Ratio to baseline UP excretion derived from 24 hour urine collection
| ratio | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline in Urine Protein (UP) Excretion | 0.57 (0.47 to 0.68) | 1.00 (0.75 to 1.33) |
Ratio to baseline UACR excretion derived from 24 hour urine collection
| ratio | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline in Urine Albumin Creatinine Concentration Ratio (UACR) Excretion | 0.55 (0.47 to 0.64) | 0.61 (0.30 to 1.27) |
Ratio to baseline UA excretion derived from 24 hour urine collection
| ratio | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline Change in Urinary Albumin (UA) Excretion | 0.57 (0.47 to 0.70) | 0.81 (0.67 to 0.98) |
Effect of LNP023 on estimated glomerular filtration rate (eGFR)
| ml/min | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) | 2.59 (0.12 to 5.06) | -0.61 (-3.36 to 2.15) |
The effect of LNP023 on renal function - serum creatinine
| mmol/L | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline in Serum Creatinine | -5.04 (-9.36 to -0.72) | 7.17 (-1.79 to 16.13) |
The effect of LNP023 on renal function - creatinine clearance
| mL/min | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline in Creatinine Clearance | 1.07 (0.99 to 1.17) | 1.20 (0.83 to 1.72) |
The effect of LNP023 on renal function - hematuria
| Participants | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Week 12: Day 84: <9 rbc/hpf n (%) | 10 | 3 |
| Week 12: Day 84: >= 9 to =<50 rbc/hpf n (%) | 0 | 0 |
| Week 12: Day 84: >50 rbc/hpf n (%) | 0 | 0 |
Ratio to baseline of UPCR reduction derived from total cumulative urinary excretion first morning void
| ratio | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline in Urine Protein to Creatinine Concentration Ratio (UPCR) First Morning Void | 0.56 (0.48 to 0.65) | 0.99 (0.76 to 1.28) |
UACR reduction derived from total cumulative urinary excretion first morning void
| g/mol | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Change From Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR) First Morning Void | 0.59 (0.50 to 0.69) | 0.87 (0.60 to 1.26) |
The area under the plasma concentration-time curve calculated from time zero to the last quantifiable concentration point (hr\*ng/mL)
| hr*ng/mL | Cohort A - no Kidney Transplant - LNP023 10mg b.i.d. | Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 10mg b.i.d. | Cohort B - Kidney Transplant - LNP023 25 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 100 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUClast (AUC) | 3690 ± 693 | 5790 ± 1630 | 13200 ± 4410 | 20300 ± 8180 | 4560 ± 2060 | 7880 ± 3830 | 19600 ± 12100 | 28100 ± 15900 |
The area under the plasma concentration-time curve calculated to the end of the dosing interval (hr\*ng/mL)
| hr*ng/mL | Cohort A - no Kidney Transplant - LNP023 10mg b.i.d. | Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 10mg b.i.d. | Cohort B - Kidney Transplant - LNP023 25 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 100 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetics of LNP023 Area Under the Plasma-concentration-time Curve AUCtau (AUC) | 5020 ± 1110 | 7970 ± 2250 | 17800 ± 5800 | 26900 ± 10900 | 6300 ± 3000 | 10700 ± 5310 | 26600 ± 16500 | 37700 ± 22000 |
The observed maximum plasma concentration (ng/mL)
| ng/mL | Cohort A - no Kidney Transplant - LNP023 10mg b.i.d. | Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 10mg b.i.d. | Cohort B - Kidney Transplant - LNP023 25 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 100 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|---|---|---|
| Observed Maximum Concentration After Drug Administration (Cmax) | 637 ± 97.1 | 941 ± 278 | 2270 ± 805 | 3600 ± 1230 | 713 ± 292 | 1280 ± 552 | 3250 ± 1790 | 4700 ± 2200 |
The concentration that is just prior to the beginning of, or at the end, of a dosing interval (ng/mL)
| ng/mL | Cohort A - no Kidney Transplant - LNP023 10mg b.i.d. | Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 10mg b.i.d. | Cohort B - Kidney Transplant - LNP023 25 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 100 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|---|---|---|
| Observed Minimum Concentration After Drug Administration (Ctrough) | 314 ± 133 | 519 ± 133 | 1090 ± 408 | 1480 ± 653 | 417 ± 237 | 644 ± 325 | 1650 ± 1010 | 2180 ± 1610 |
The time to reach peak or maximum concentration (hr)
| hr | Cohort A - no Kidney Transplant - LNP023 10mg b.i.d. | Cohort A - no Kidney Transplant - LNP023 25 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 100 mg b.i.d. | Cohort A -no Kidney Transplant - LNP023 200 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 10mg b.i.d. | Cohort B - Kidney Transplant - LNP023 25 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 100 mg b.i.d. | Cohort B - Kidney Transplant - LNP023 200 mg b.i.d. |
|---|---|---|---|---|---|---|---|---|
| Time to Reach the Maximum Plasma Concentration (Tmax) | 2.00 (0.800 to 6.00) | 2.00 (0.900 to 4.00) | 2.00 (0.500 to 4.00) | 2.00 (1.00 to 4.00) | 2.00 (1.00 to 4.00) | 2.00 (1.00 to 6.00) | 2.00 (1.00 to 4.00) | 2.00 (1.00 to 4.00) |
To assess the effect of LNP023 on alternative complement pathway hyperactivity.
| g/L | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Day 1 pre-dose | 0.0 ± 0.06 | 0.0 ± 0.12 |
| Day 7 - pre-dose | 0.1 ± 0.10 | 0.2 ± 0.22 |
| Day 14 - pre-dose | 0.3 ± 0.17 | 0.4 ± 0.29 |
| Day 21 - pre-dose | 0.5 ± 0.25 | 0.4 ± 0.33 |
| Day 28 - pre-dose | 0.5 ± 0.29 | 0.4 ± 0.27 |
| Day 36 - pre-dose | 0.6 ± 0.28 | 0.4 ± 0.32 |
| Day 64 - pre-dose | 0.6 ± 0.27 | 0.4 ± 0.26 |
| Day 84 - pre-dose | 0.6 ± 0.30 | 0.5 ± 0.26 |
To assess the relationship between LNP023 dose and pharmacodynamic biomarker levels of blood Bb
| Ratio of plasma Bb | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant |
|---|---|---|
| Day 1 pre-dose | 101.8 ± 45.18 | 109.7 ± 34.08 |
| Day 7 pre-dose | 102.4 ± 40.47 | 83.6 ± 27.73 |
| Day 14 pre-dose | 104.4 ± 43.35 | 81.8 ± 39.34 |
| Day 21 pre-dose | 97.0 ± 58.06 | 66.4 ± 22.95 |
| Day 28 pre-dose | 90.2 ± 46.24 | 71.5 ± 29.52 |
| Day 36 pre-dose | 102.5 ± 54.06 | 65.9 ± 31.20 |
| Day 64 pre-dose | 116.8 ± 59.76 | 73.2 ± 29.62 |
| Day 84 pre-dose | 116.6 ± 57.85 | 76.3 ± 35.84 |
Collected over Adverse Events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of approximately 2 years, 2 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A - Run-in Phase | 0/16 (0%) | 0/16 (0%) | 0/16 (0%) |
| Cohort A - Dose Escalation Phase | 0/16 (0%) | 0/16 (0%) | 6/16 (37.5%) |
| Cohort A - LNP023 200mg b.i.d | 0/16 (0%) | 0/16 (0%) | 8/16 (50%) |
| Cohort B - Run-in Phase | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Cohort B - Dose Escalation Phase | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| Cohort B - LNP023 200mg b.i.d | 0/11 (0%) | 2/11 (18.2%) | 6/11 (54.5%) |
| Event | Cohort A - Run-in Phase | Cohort A - Dose Escalation Phase | Cohort A - LNP023 200mg b.i.d | Cohort B - Run-in Phase | Cohort B - Dose Escalation Phase | Cohort B - LNP023 200mg b.i.d |
|---|---|---|---|---|---|---|
| OverdoseInjury, poisoning and procedural complications | 0/16 | 0/16 | 0/16 | 0/11 | 0/11 | 1/11 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/16 | 0/16 | 0/16 | 0/11 | 0/11 | 1/11 |
| Event | Cohort A - Run-in Phase | Cohort A - Dose Escalation Phase | Cohort A - LNP023 200mg b.i.d | Cohort B - Run-in Phase | Cohort B - Dose Escalation Phase | Cohort B - LNP023 200mg b.i.d |
|---|---|---|---|---|---|---|
| HyperkalaemiaMetabolism and nutrition disorders | 0/16 | 0/16 | 0/16 | 0/11 | 0/11 | 2/11 |
| HeadacheNervous system disorders | 0/16 | 0/16 | 0/16 | 0/11 | 2/11 | 0/11 |
| Conjunctival hyperaemiaEye disorders | 0/16 | 0/16 | 0/16 | 0/11 | 1/11 | 0/11 |
| DyspepsiaGastrointestinal disorders | 0/16 | 0/16 | 0/16 | 0/11 | 1/11 | 0/11 |
| NauseaGastrointestinal disorders | 0/16 | 0/16 | 0/16 | 0/11 | 0/11 | 1/11 |
| VomitingGastrointestinal disorders | 0/16 | 1/16 | 0/16 | 0/11 | 0/11 | 1/11 |
| COVID-19Infections and infestations | 0/16 | 0/16 | 0/16 | 0/11 | 0/11 | 1/11 |
| HordeolumInfections and infestations | 0/16 | 0/16 | 0/16 | 0/11 | 0/11 | 1/11 |
| InfluenzaInfections and infestations | 0/16 | 0/16 | 0/16 | 0/11 | 0/11 | 1/11 |
| NasopharyngitisInfections and infestations | 0/16 | 0/16 | 0/16 | 0/11 | 1/11 | 0/11 |
For all analysis sets, patients were analyzed according to study drug received for Cohort A and B. Safety analysis set included all patients that received any study drug. PK analysis set included all patients with available PK data and no protocol deviations with relevant impact on PK data.
| Age, Customized(Years) | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant | Total |
|---|---|---|---|
| Median | 22.0 (18 to 59) | 31.0 (18 to 70) | 24.0 (18 to 70) |
| Sex: Female, Male(Participants) | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant | Total |
|---|---|---|---|
| Female | 6 | 3 | 9 |
| Male | 10 | 8 | 18 |
| Race/Ethnicity, Customized(Participants) | Cohort A - no Kidney Transplant | Cohort B - Kidney Transplant | Total |
|---|---|---|---|
| American Indian or Alaska | 0 | 1 | 1 |
| Black or African American | 0 | 1 | 1 |
| White | 16 | 9 | 25 |
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 16 | 8 | 24 |
| Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Feb 2019 to primary completion in Apr 2021, 26 months.
Results were first posted in Jul 2022, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iptacopan